Nonexudative Macular Neovascularization in Age-Related Macular Degeneration - Report - MDSpire

Nonexudative Macular Neovascularization in Age-Related Macular Degeneration

  • By

  • Sridevi Thottarath

  • Sarega Gurudas

  • Syed Kubravi

  • Dimitrios Kazantzis

  • Ayse Merve Keskin

  • Sobha Sivaprasad

  • EYENEON Study Group

  • Benjamin Burton

  • Geeta Menon

  • Manju Chandran

  • Ian Pearce

  • Savita Madhusudhan

  • Anna Grabowska

  • Faruque Ghanchi

  • James Talks

  • Richard Gale

  • Martin McKibbin

  • Ajay Kotagiri

  • Niro Narendran

  • Afsar Jafree

  • Saad Younis

  • Claire Bailey

  • Priya Prakash

  • Christiana Dinah

  • Louise Downey

  • Andrew Lottery

  • Paritosh Shah

  • Romi Chhabra

  • Narendra Dhingra

  • Indra Dias

  • Mary Freeman

  • Daren Hanumunthadu

  • May 1, 2026

  • 0 min

Share

Clinical Report: Subclinical Nonexudative Macular Neovascularization in AMD

Overview

This study investigates the prevalence of subclinical nonexudative macular neovascularization (neMNV) in fellow eyes of patients with unilateral exudative age-related macular degeneration (AMD). The findings highlight the association between double-layer sign (DLS) and neMNV, emphasizing the need for careful monitoring of at-risk eyes.

Background

Age-related macular degeneration (AMD) is a leading cause of visual impairment in older adults, particularly due to the transition from nonexudative to exudative forms. Understanding the presence of subclinical neMNV is crucial, as it serves as a significant risk factor for the development of exudative AMD. Enhanced detection and monitoring strategies are essential for timely intervention and prevention of vision loss.

Data Highlights

No numerical data available in the provided source material.

Key Findings

  • Subclinical neMNV is present in fellow eyes of patients with unilateral exudative AMD.
  • Prevalence of neMNV in fellow eyes varies widely, reported between 6.25% and 27.00%.
  • DLS may serve as a surrogate marker for neMNV, but its reliability is uncertain.
  • Dimensions of DLS greater than 1000 μm are more likely to harbor neMNV.
  • Monitoring fellow eyes is critical, as conversion rates to exudative AMD range from 12% to 38.7% over 5 years.

Clinical Implications

Clinicians should prioritize regular imaging and monitoring of fellow eyes in patients with unilateral exudative AMD to detect neMNV early. Understanding the limitations of DLS as a surrogate for neMNV is essential for guiding treatment decisions and patient management.

Conclusion

The study underscores the importance of recognizing subclinical neMNV as a risk factor for exudative AMD, advocating for vigilant surveillance in at-risk populations to prevent vision loss.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. Retinal Physician, Treatment of Pigment Epithelial Detachments in Age-Related Macular Degeneration, 2018 -- Title
  3. New Retinal Physician, So You Have Diagnosed MacTel—Now What?, 2022 -- Title
  4. optometric management, Advanced AMD Monitoring Using OCT-A, 2025 -- Title
  5. Age-Related Macular Degeneration Preferred Practice Pattern® - PubMed, 2024 -- Title
  6. Aflibercept Injection as Prophylaxis Against Conversion to Exudative AMD in High-risk Eyes, 2021 -- Title
  7. OCTA in age-related macular degeneration: consensus on practical guidelines for optimal imaging strategies across different clinical scenarios, 2026 -- Title
  8. Age-Related Macular Degeneration Preferred Practice Pattern® - PubMed
  9. Aflibercept Injection as Prophylaxis Against Conversion to Exudative AMD in High-risk Eyes
  10. OCTA in age-related macular degeneration: consensus on practical guidelines for optimal imaging strategies across different clinical scenarios | Graefe's Archive for Clinical and Experimental Ophthalmology | Springer Nature Link

Original Source(s)

Nonexudative Macular Neovascularization in Age-Related Macular Degeneration

  • by Sridevi Thottarath, Sarega Gurudas, Syed Kubravi, Dimitrios Kazantzis, Ayse Merve Keskin, Sobha Sivaprasad, EYENEON Study Group, Benjamin Burton, Geeta Menon, Manju Chandran, Ian Pearce, Savita Madhusudhan, Anna Grabowska, Faruque Ghanchi, James Talks, Richard Gale, Martin McKibbin, Ajay Kotagiri, Niro Narendran, Afsar Jafree, Saad Younis, Claire Bailey, Priya Prakash, Christiana Dinah, Louise Downey, Andrew Lottery, Paritosh Shah, Romi Chhabra, Narendra Dhingra, Indra Dias, Mary Freeman, Daren Hanumunthadu

  • May 1, 2026

Related Content

Trends and Key Areas of Research in the Pathophysiology, Imaging, and Treatment of Type 3 Macular Neovascularization (MNV3) Associated with Age-Related Macular Degeneration (AMD)

Suspected Ocular Toxoplasmosis in Patients with ABCA4-Related Maculopathy

Centre for Sight launches "Eye Health MOT"

New service offers advanced diagnostics, early detection and reassurance

  • February 13, 2026

  • 2 min